They also appear somewhat indifferent to filling in the gaps for investors that might otherwise give greater confidence to holding for the longer term. By now, for example, I’d really like to know what the contract services division is up to at the US manufacturing facility, and what contribution this is making to repaying the capex spent on establishing it. They are capable of at least 1 billion+ capsules/tabs per annum output - so is it being fully utilised, are there fulfilment orders from other drug/drug development companies underway there, what is the facility largely producing at this point - is it mainly only our generic lines, what % capacity is it running at, if spare then what is in the negotiation pipeline to fill it? etc etc. This was large capital expenditure, you’d think it would be an attractive asset, and it would be nice to get a better sense of how it is now earning its keep. Likewise the older Aus facility.
MYX Price at posting:
38.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)